Keyphrases
Nuclear Factor Erythroid 2-related Factor 2 (Nrf2)
100%
Acute Myeloid Leukemia Cells
100%
Antioxidant Response
100%
Valproic Acid
100%
Reactive Oxygen Species
100%
AML Cells
60%
Refractory AML
40%
Medroxyprogesterone Acetate
40%
Relapsed or Refractory
40%
Bezafibrate
40%
Therapeutic Combinations
20%
Lipid Inhibition
20%
Safety Data
20%
Contraceptive Hormones
20%
Dose-limiting Toxicity
20%
Lipid-lowering Agents
20%
High Dose
20%
Phase II Trial
20%
Drug Repurposing
20%
Good Safety
20%
Overexpression
20%
K562
20%
Reactive Oxygen Species Production
20%
Antiepileptic Drugs
20%
KG-1a
20%
In Vivo Efficacy
20%
Lipid Peroxidation
20%
In Vivo Safety
20%
Novel Therapeutics
20%
Improved Outcomes
20%
Fatty Acid Synthesis
20%
High-risk Myelodysplastic Syndrome
20%
In Vitro Killing
20%
Pharmacology, Toxicology and Pharmaceutical Science
Sodium Valproate
100%
Antioxidant
100%
Acute Myeloid Leukemia
100%
Transcription Factor Nrf2
100%
Reactive Oxygen Metabolite
100%
Bezafibrate
40%
Medroxyprogesterone Acetate
40%
Fatty Acid
20%
Myelodysplastic Syndrome
20%
Phase II Trials
20%
Antilipemic Agent
20%
Epilepsy
20%
Immunology and Microbiology
Transcription Factor Nrf2
100%
Leukemia Cell
100%
Myeloid
100%
Low Drug Dose
100%
Fatty Acid Synthesis
33%
Drug Megadose
33%
Lipid Peroxidation
33%
Primary Cell Line
33%